PD-L1 testing as a way of personalizing the treatment of non-small cell lung cancer
Open Access
- 26 September 2019
- journal article
- Published by LLC Information and Research Center Likarska Sprava in Likars'ka Sprava
- No. 5-6,p. 40-45
- https://doi.org/10.31640/jvd.5-6.2019(4)
Abstract
Lung cancer is one of the main causes of death from malignant neoplasm all around the world. For the purpose of personalized treatment immunohistochemical determination of specific proteins (biomarkers) presence in tissues and biological fluids is needed. Today management of patients with lung cancer is directly associated with determination of genes mutations: EGFR, ALK, ROS1 and rate of PD-L1 receptors expression. Depending on the PD-L1 expression level blockers of these receptors can be used as the first, supportive and second / third line therapy. As the first line of therapy for patients with high expression level of PD-L1 (≥ 50 % TPS) Pemblizomab is recommended, while for patients with moderate levels (PD-L1 1 – 49% TPS) PD-L1 blockers can be used only as a second / third line of therapy. In numerous clinical trials efficiency and safety of Pemrolizumab, Nivolumab and Atezolizumab have been proved. Testing of Avelumab, Durvalumab, as well as combined drugs – Ipilimumab and Tremilimumb are still going on.Keywords
This publication has 14 references indexed in Scilit:
- Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2017
- PL04a.03: Durvalumab in ≥3rd-Line Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC StudyJournal of Thoracic Oncology, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2016
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trialThe Lancet Oncology, 2016
- Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).Journal of Clinical Oncology, 2016
- Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b studyThe Lancet Oncology, 2016
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2015
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled TrialsJournal of Clinical Oncology, 2008